A STUDY OF PHARMACOLOGY OF 17-HYDROXYPROGESTERONE CAPROATE IN PREGNANCY

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 这是一项由NICHD资助的多中心研究，由产科药理学研究单位（OPRU）网络进行，旨在确定17-OHPC在妊娠期的药理学：其药代动力学、代谢和药物的胎盘转运。17-OHPC用于预防早产。60例妊娠女性将在妊娠期间接受3次研究（2项PK研究和胎盘研究）。 分娩期间的运输），沿着可选的第四项研究。将有15名与会者在GU现场。受试者将从入组至妊娠35周每周接受一次17-OHPC IM注射，参与研究的时间约为15周。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a multi-center NICHD funded study, conducted by the Obstetrical Pharmacology Research Unit (OPRU) network, to define the pharmacology of 17-OHPC in pregnancy: its pharmacokinetics, metabolism and placental transport of the drug. 17-OHPC is used to prevent preterm labor. Sixty pregnant women will be studied three times during their pregnancies (two PK studies, and placental transport during labor & delivery), along with an optional fourth study. There will be 15 participants at the GU site. Participants will receive weekly IM injections of 17-OHPC from enrollment until 35 weeks gestation, with length of participation in study about 15 weeks.